Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. has announced the convening of its 2025 first class meeting of H shareholders to consider significant resolutions, including the change of registered capital, the cancellation of the supervisory committee, and amendments to the company’s Articles of Association and Rules of Procedures. These proposed changes are expected to streamline the company’s governance structure and potentially enhance operational efficiency, reflecting a strategic move to strengthen its market position and stakeholder engagement.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is focused on developing innovative biologic drugs, primarily targeting oncology and autoimmune diseases.
Average Trading Volume: 9,367,111
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.81B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue